Bai Yongtai, Li Kai, Peng Jinying, Yi Chengqi
State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing 100871, China.
Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
Life Med. 2023 Apr 8;2(1):lnad008. doi: 10.1093/lifemedi/lnad008. eCollection 2023 Feb.
To date, over 170 different kinds of chemical modifications on RNAs have been identified, some of which are involved in multiple aspects of RNA fate, ranging from RNA processing, nuclear export, translation, and RNA decay. mA, also known as -methyladenosine, is a prominent internal RNA modification that is catalyzed primarily by the METTL3-METTL14-WTAP methyltransferase complex in higher eukaryotic mRNA and long noncoding RNA (lncRNA). In recent years, abnormal mA modification has been linked to the occurrence, development, progression, and prognosis of the majority of cancers. In this review, we provide an update on the most recent mA modification discoveries as well as the critical roles of mA modification in cancer development and progression. We summarize the mechanisms of mA involvement in cancer and list potential cancer therapy inhibitors that target mA regulators such as "writer" METTL3 and "eraser" FTO.
迄今为止，已鉴定出超过170种不同的RNA化学修饰，其中一些参与RNA命运的多个方面，包括RNA加工、核输出、翻译和RNA降解。mA，也称为N6-甲基腺苷，是一种显著的内部RNA修饰，在高等真核生物mRNA和长链非编码RNA（lncRNA）中主要由METTL3-METTL14-WTAP甲基转移酶复合物催化。近年来，异常的mA修饰与大多数癌症的发生、发展、进展和预后有关。在本综述中，我们提供了关于mA修饰最新发现的最新信息，以及mA修饰在癌症发展和进展中的关键作用。我们总结了mA参与癌症的机制，并列出了靶向mA调节剂（如“书写者”METTL3和“擦除者”FTO）的潜在癌症治疗抑制剂。
